Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadofaragene Firadenovec Reinduction in NMIBC
NCT06390111Phase 4Withdrawn
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 4 trial of nadofaragene firadenovec in non-muscle-invasive bladder cancer (NMIBC), sponsored by Ferring Pharmaceuticals. Planned start Jun 2024; status: withdrawn.
02
Drugs
nadofaragene firadenovec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06390111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390111.